J Am Coll Cardiol
New guideline streamlines acute pulmonary embolism care with risk-based approach
The 2026 AHA/ACC–led multisociety guideline provides an updated, unified framework for the evaluation and management of acute pulmonary embolism (PE) in adults, emphasizing rapid diagnosis, evidence-based risk stratification, and tailored therapy across care settings. The document reflects growing use of clinical prediction rules, age-adjusted D‑dimer testing, and direct oral anticoagulants (DOACs), while clarifying indications for thrombolysis, catheter-based interventions, and multidisciplinary PE response teams (PERTs). A central focus is identifying low-risk patients appropriate for early discharge and ensuring structured follow-up to reduce complications, including chronic thromboembolic pulmonary hypertension (CTEPH).
Key recommendations
Diagnostic strategy
- Apply validated clinical prediction tools (eg, Wells or Geneva score) to estimate pretest probability.
- In low-risk patients, use age-adjusted D‑dimer thresholds to safely exclude PE and reduce unnecessary imaging.
- CT pulmonary angiography remains first-line imaging when PE cannot be ruled out clinically; V/Q scanning is reasonable when CTPA is contraindicated.
Risk stratification
- Classify PE as high risk (massive), intermediate risk (submassive), or low risk using hemodynamics, right ventricular (RV) imaging, biomarkers (troponin, BNP), and PESI or sPESI scores.
- Risk category should directly guide site of care, anticoagulant choice, and consideration of advanced therapies.
Initial anticoagulation
- Start anticoagulation promptly once PE is suspected and bleeding risk is acceptable.
- DOACs are preferred over vitamin K antagonists for most hemodynamically stable patients due to comparable efficacy, lower intracranial bleeding risk, and easier outpatient use.
- Parenteral anticoagulation (UFH or LMWH) is favored in patients with high-risk PE, anticipated need for procedures, severe renal dysfunction, or uncertain absorption.
- In cancer-associated PE, LMWH or selected DOACs are appropriate, with careful attention to bleeding risk and drug–drug interactions.
Duration and intensity of anticoagulation
- Treat all patients for a minimum of 3 months.
- After 3 months, individualize extended therapy based on provoking factors, recurrence risk, bleeding risk, and patient preference.
- Reduced-dose DOAC regimens may be considered for long-term secondary prevention in appropriate patients.
Reperfusion and advanced therapies
- Systemic thrombolysis is recommended for patients with high-risk PE and sustained hypotension, unless contraindicated.
- For intermediate-risk PE with clinical deterioration or high bleeding risk, consider catheter-directed thrombolysis or thrombectomy.
- Surgical embolectomy is an option when thrombolysis is contraindicated or ineffective.
- Multidisciplinary PE response teams (PERTs) are encouraged for complex cases requiring rapid escalation.
Disposition and follow-up
- Carefully selected low-risk patients may be managed entirely as outpatients with early DOAC initiation and close follow-up.
- All patients should have structured post-PE reassessment to evaluate symptoms, anticoagulation adherence, and screen for CTEPH if dyspnea persists.
Source:
Creager MA, et al. (2026, February 19). J Am Coll Cardiol. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. https://pubmed.ncbi.nlm.nih.gov/41712898/
